TG Therapeutics (TGTX) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and TG Therapeutics published the results on November 9, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• Q3 2025 net income of $390.9 million, and diluted EPS of $2.43, included a non-recurring income tax benefit of about $365.0 million from releasing TG Therapeutics' deferred tax asset valuation allowance. Q3 2026 carries a normal tax expense of $18.4 million.
• The BRIUMVI U.S. row is part of product revenue, net; the rest of product revenue is BRIUMVI sold to ex-U.S. partner Neuraxpharm. U.S. figures are in millions as the release prints them.

Source: TG Therapeutics Q3 2026 results, November 9, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How TG Therapeutics splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• TG Therapeutics's Product revenue, net revenue was $240 million in Q3 2026, up 51% from $159 million in Q3 2025, 92% of total revenue.
• TG Therapeutics's License, milestone, royalty and other revenue revenue was $19.9 million in Q3 2026, up 732% from $2.4 million in Q3 2025, 8% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, TG Therapeutics said:

“Raises full year 2026 target total global revenue to approximately $1 billion”

“Raises full year 2026 target BRIUMVI U.S. net product revenue to approximately $915-$920 million”

“Reaffirms full year 2026 target operating expense (R&D and SG&A excluding non-cash compensation) guidance, of approximately $450-$500 million including expenses associated with the subcutaneous BRIUMVI manufacturing costs and secondary manufacturer start-up costs”

Source: TG Therapeutics Q3 2026 release, Nov 9, 2026.

This is the company's own guidance as of Nov 9, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the TGTX forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP total revenue and diluted net income per common share, each as first reported in that quarter's release. Q3 2025 EPS includes the one-off tax benefit from releasing the deferred tax asset valuation allowance.

We do not hold a confirmed date for TG Therapeutics's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 9, 2026

TG Therapeutics reported total revenue of $259.9 million for Q3 2026, up 61% from $161.7 million. Nearly all of it comes from one drug, BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody given by IV infusion to adults with relapsing forms of multiple sclerosis (RMS). (TG Therapeutics Q3 2026 release, Nov 9, 2026)

BRIUMVI U.S. net product revenue was $232.6 million, about a 52% increase from $152.9 million a year earlier. Product revenue, net, $240.0 million in total, also includes $7.4 million of BRIUMVI sold to TG's ex-U.S. licensing partner, Neuraxpharm. (TG Therapeutics Q3 2026 release, Nov 9, 2026; TG Therapeutics Form 10-Q, Q3 2026, Nov 9, 2026)

License, milestone, royalty and other revenue jumped to about $19.9 million from about $2.4 million. It was mostly $15.8 million of license, milestone and other revenue and $4.1 million of royalty revenue under the Commercialization Agreement with the ex-U.S. partner. (TG Therapeutics Q3 2026 release, Nov 9, 2026)

TG is working on new ways to give BRIUMVI. The Phase 3 ENHANCE trial showed bioequivalent drug exposure for a single 600mg initiation infusion against the approved two-infusion start, and TG expects a potential launch of simplified IV initiation in mid-2027. Top-line Phase 3 data for a subcutaneous version are expected by year-end 2026 or early 2027, with a potential subcutaneous launch in 2028. (TG Therapeutics Q3 2026 release, Nov 9, 2026)

TG Therapeutics' diluted EPS fell to $0.35 from $2.43, even though operating income nearly tripled to $85.9 million from $29.4 million. The year-ago quarter included a non-recurring income tax benefit of about $365.0 million from releasing the valuation allowance on its deferred tax assets; Q3 2026 instead had an income tax expense of $18.4 million. TG reports no adjusted EPS. (TG Therapeutics Q3 2026 release, Nov 9, 2026)

Costs rose with the launch and pipeline. R&D was about $51.3 million against $40.9 million, mainly for subcutaneous manufacturing, a secondary manufacturer and clinical trials, and SG&A was about $80.7 million against $63.4 million on marketing, media and personnel. Interest expense rose to $15.8 million from $6.7 million after TG replaced its term loan with a new $750 million term loan facility from Blue Owl Capital on March 18, 2026. (TG Therapeutics Q3 2026 release, Nov 9, 2026; TG Therapeutics Form 10-Q, Q3 2026, Nov 9, 2026)

TG repurchased about $100 million of stock in Q3 2026, about 2.0 million shares at an average $49.43. Through the end of the quarter it had repurchased $300 million, 8.9 million shares or about 6% of shares outstanding, at an average $33.88. Diluted weighted-average shares were 155,925,050 against 160,997,977. (TG Therapeutics Q3 2026 release, Nov 9, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

TG Therapeutics gives full-year revenue and expense targets in its release and raised the revenue targets this quarter. For 2026 it now targets total global revenue of about $1 billion, up from about $950 million, and BRIUMVI U.S. net product revenue of about $915 million to $920 million, up from $890 million to $905 million. It reaffirmed operating expense guidance, R&D and SG&A excluding non-cash compensation, of about $450 million to $500 million. (TG Therapeutics Q3 2026 release, Nov 9, 2026)

A consensus figure is the average of the models published by the analysts who cover TG Therapeutics, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones TG Therapeutics's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning TGTX is on is TGTX a buy or a sell?, what analysts expect next is on the TGTX forecast, and what the company does is on the TG Therapeutics (TGTX) stock page.

Every number on this page can be traced to a document TG Therapeutics published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.